Compile Data Set for Download or QSAR
Report error Found 66 Enz. Inhib. hit(s) with all data for entry = 129
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50: 1.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50: 2.30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026827(US9669035, B-6 | CHEMBL3331516)
Affinity DataIC50: 4.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026829(US9669035, B-7 | CHEMBL3331514)
Affinity DataIC50: 6.20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026828(US9669035, B-8 | CHEMBL3331515)
Affinity DataIC50: 6.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026821(US9669035, B-1b | CHEMBL3331521 | US11419874, Exam...)
Affinity DataIC50: 7.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026826(US9669035, B-2 | CHEMBL3331517 | US11419874, Examp...)
Affinity DataIC50: 7.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179970(US9669035, B-9)
Affinity DataIC50: 9.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026820(US9669035, B-10 | CHEMBL3331513)
Affinity DataIC50: 10nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179972(US9669035, B-11)
Affinity DataIC50: 11nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026825(US9669035, B-12 | CHEMBL3331518)
Affinity DataIC50: 12nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026821(US9669035, B-1b | CHEMBL3331521 | US11419874, Exam...)
Affinity DataIC50: 13nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50: 14nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181755(US9669035, B-25)
Affinity DataIC50: 18nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50: 20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179977(US9669035, B-14)
Affinity DataIC50: 21nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179978(US9669035, B-15)
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181763(US9669035, B-26)
Affinity DataIC50: 22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026824(US9669035, B-16 | CHEMBL3331519)
Affinity DataIC50: 30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50: 34nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179980(US9669035, B-17)
Affinity DataIC50: 35nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179981(US9669035, B-18)
Affinity DataIC50: 36nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181676(US9669035, B-22a)
Affinity DataIC50: 44nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179983(US9669035, B-20)
Affinity DataIC50: 45nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179982(US9669035, B-19)
Affinity DataIC50: 46nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181673(US9669035, B-21)
Affinity DataIC50: 49nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181678(US9669035, B-23)
Affinity DataIC50: 52nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182096(US9669035, B-27)
Affinity DataIC50: 74nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179970(US9669035, B-9)
Affinity DataIC50: 85nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182226(US9669035, B-28)
Affinity DataIC50: 91nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026820(US9669035, B-10 | CHEMBL3331513)
Affinity DataIC50: 100nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50: 110nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182234(US9669035, B-29)
Affinity DataIC50: 120nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182294(US9669035, B-30)
Affinity DataIC50: 130nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50: 160nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181713(US9669035, B-24)
Affinity DataIC50: 190nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026829(US9669035, B-7 | CHEMBL3331514)
Affinity DataIC50: 260nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026825(US9669035, B-12 | CHEMBL3331518)
Affinity DataIC50: 270nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026828(US9669035, B-8 | CHEMBL3331515)
Affinity DataIC50: 320nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179981(US9669035, B-18)
Affinity DataIC50: 320nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182857(US9669035, B-31)
Affinity DataIC50: 330nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182858(US9669035, B-32)
Affinity DataIC50: 350nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181676(US9669035, B-22a)
Affinity DataIC50: 910nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182857(US9669035, B-31)
Affinity DataIC50: 1.40E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179978(US9669035, B-15)
Affinity DataIC50: 1.50E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026826(US9669035, B-2 | CHEMBL3331517 | US11419874, Examp...)
Affinity DataIC50: 1.60E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179980(US9669035, B-17)
Affinity DataIC50: 1.60E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179977(US9669035, B-14)
Affinity DataIC50: 1.80E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rat)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026827(US9669035, B-6 | CHEMBL3331516)
Affinity DataIC50: 1.90E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: